- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kite Pharma Reports Positive Data From ZUMA-1, Evaluating a CAR-T Treatment
Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.
Kite Pharma, a pioneer in developing the chimeric antigen receptor (CAR)-T cell treatment, has announced that median overall survival (OS) was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.
The trial, being conducted in patients with chemotherapy-resistant aggressive B-cell non-Hodgkin lymphoma (NHL), is testing axicabtagene ciloleucel (previously referred to as KTE-C19). Interim analysis of the data showed that the trial met its primary endpoints of objective response rate (ORR), complete response (CR), and partial response (PR), following a single infusion of axicabtagene ciloleucel.
Of the 101 trial participants, 41% achieved ORR at 6 months (P <.0001), 36% had a CR, and 5% of patients had a durable PR. One of the partial responders became a complete responder at 9 months following infusion. More importantly, the trial was yet to reach a median OS at nearly 9 months of follow-up.
The following grade 3 or higher adverse events were reported from the trial:
- Anemia (43%)
- Neutropenia (39%)
- Decreased neutrophil count (32%)
- Febrile neutropenia (31%)
- Decreased white blood cell count (29%)
- Thrombocytopenia (24%)
- Encephalopathy (21%)
- Decreased lymphocyte count (20%)
No cases of cerebral edema were reported, unlike the JCAR015 trial. Grade 3 or higher cytokine release syndrome, very commonly observed with CAR-T treatment, decreased from 18% to 13%.
“Several patients we treated at Moffitt Cancer Center experienced a rapid and durable complete response with this first-of-its kind therapy,” Frederick L. Locke, MD, ZUMA-1 co-lead investigator, and director of research for the Immune Cell Therapy Program at Moffitt Cancer Center, said in a statement. "The ZUMA-1 study results suggest that axicabtagene ciloleucel could become a new standard of care for patients with refractory aggressive lymphoma."
The company is planning to submit a rolling Biologics License Application based on these results by the end of the first quarter of 2017.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
